HC Wainwright & Co. Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $25

Benzinga · 4d ago
HC Wainwright & Co. analyst Arthur He initiates coverage on Jade Biosciences (NASDAQ:JBIO) with a Buy rating and announces Price Target of $25.